Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1230-1237

  Yang, Jinsheng ^a   Xiao, Zheng ^a   Li, Tao ^a   Gu, Xuanmin ^a   Fan, Bo ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; Erythropoietin; Pituitary adenoma

Indexed keywords

JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; VASCULOTROPIN;

ADOLESCENT; ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL PROLIFERATION; CHORIOALLANTOIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ADOLESCENT; ADULT; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; PROLINE; RATS; RECEPTORS, ERYTHROPOIETIN; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84863369192     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1261     Document Type: Article

References (33)

1. Ng T, Marx G, Littlewood T and Macdougall I: Recombinant erythropoietin in clinical practice. Postgrad Med J 79: 367-376, 2003. (Pubitemid 36993965)
2. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460, 2003.
3. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003. (Pubitemid 37324251)
4. Jelkmann W, Bohlius J, Hallek M and Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67: 39-61, 2008.
5. Glaspy JA: Erythropoiesis-stimulating agents in oncology. J Natl Compr Cancer Netw 6: 565-575, 2008.
6. Glaspy J, Crawford J, Vansteenkiste J, et al: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102: 301-315, 2010.
7. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972, 2005.
8. Temkin SM, Hellmann M, Serur E, Lee YC and Abulafia O: Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 16: 1855-1861, 2006. (Pubitemid 44470046)
9. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032, 2007. (Pubitemid 46596751)
10. Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26: 1040-1050, 2008.
11. Thomas G, Ali S, Hoebers FJ, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108: 317-325, 2008.
12. Lee YS, Vortmeyer AO, Lubensky IA, et al: Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11: 1059-1064, 2005. (Pubitemid 40175754)
13. Saintigny P, Besse B, Callard P, et al: Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 13: 4825-4831, 2007. (Pubitemid 47294790)
14. Lai SY, Childs EE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24: 4442-4449, 2005. (Pubitemid 40961767)
15. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W and Haroon ZA: Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18: 421-430, 2005. (Pubitemid 40395362)
16. Jeong JY, Feldman L, Solar P, Szenajch J and Sytkowski AJ: Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122: 274-280, 2008. (Pubitemid 350234712)
17. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565, 2001. (Pubitemid 32694960)
18. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF and Laws ER Jr: Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 98: 974-977, 2003. (Pubitemid 36460887)
19. Shimon I, Benbassat C, Tzvetov G and Grozinsky-Glasberg S: Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14: 11-15, 2011.
20. Aron DC, Tyrrell JB and Wilson CB: Pituitary tumors. Current concepts in diagnosis and management. West J Med 162: 340-352, 1995.
21. Ribatti D: Erythropoietin and tumor angiogenesis. Stem Cells Dev 19: 1-4, 2010.
22. Funamoto M, Fujio Y, Kunisada K, et al: Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 275: 10561-10566, 2000. (Pubitemid 30202121)
23. Szenajch J, Wcislo G, Jeong JY, Szczylik C and Feldman L: The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta 1806: 82-95, 2010.
24. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006. (Pubitemid 43166118)
25. Mohyeldin A, Lu H, Dalgard C, et al: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7: 537-543, 2005. (Pubitemid 40791872)
26. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K and Arai H: Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10: 932-939, 2008.
27. Ribatti D, Vacca A, Roccaro AM, Crivellato E and Presta M: Erythropoietin as an angiogenic factor. Eur J Clin Invest 33: 891-896, 2003. (Pubitemid 37215045)
28. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B and Vacca A: Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 50: 636-641, 2007. (Pubitemid 46495823)
29. Anagnostou A, Lee ES, Kessimian N, Levinson R and Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978-5982, 1990.
30. Hardee ME, Cao Y, Fu P, et al: Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2: e549, 2007.
31. Asaumi Y, Kagaya Y, Takeda M, et al: Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 115: 2022-2032, 2007. (Pubitemid 46625953)
32. Osugi T, Oshima Y, Fujio Y, et al: Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 277: 6676-6681, 2002. (Pubitemid 34968469)
33. Hilfiker-Kleiner D, Limbourg A and Drexler H: STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 15: 152-157, 2005. (Pubitemid 41138880)